• About us
• Contact

Advertisement

Organisation › Details

LSP 6 fund (Life Sciences Partners)

Launched in 2014, LSP 5 targets investment opportunities in healthcare companies developing pioneering products and technologies that provide solutions to unmet medical needs, similar to its predecessor funds. The fund will invest in around 20 companies across the areas of drug development, medical devices and diagnostics. LSP partners René Kuijten, Joachim Rothe, Martijn Kleijwegt, Joerg Neermann, John de Koning and Fouad Azzam have worked together for a decade and combine entrepreneurial and financial skills with a strong background in biosciences and medicine. *

 

	Start	2018-11-12 existent
	Group	EQT (Wallenberg family) (Group)
	Predecessor	LSP 5 fund (Life Sciences Partners)
	Successor	LSP 7 fund (Life Sciences Partners)
	Industry	LSP 6 fund (Life Sciences Partners)
	Industry 2	LIFE SCIENCES
	Person	Kuijten, René R. (Life Sciences Partners 201403 General Partner)
	Person 2	Rothe, Joachim G. (Life Sciences Partners München 201511 Partner)
	Region	Amsterdam
	Country	Netherlands
	City	n. a.
		Address record changed: 2018-11-15
Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	410,000,000 (fund size 2018-11-12)
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for EQT (Wallenberg family) (Group)

• [1] FundaMental Pharma GmbH. (3/20/24). "Press Release: FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director". Heidelberg....
• [2] Tubulis GmbH. (3/14/24). "Press Release: Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline". Munich....
• [3] Shinobi Therapeutics Inc.. (12/12/23). "Press Release: Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform". San Francisco, CA & Kyoto....
• [4] VectorY Therapeutics B.V.. (11/13/23). "Press Release: VectorY Raises €129 Million ($138 Million) Series A Financing to Advance Vectorized Antibody Programs in Neurodegenerative Diseases". Amsterdam....
• [5] EQT AB. (6/21/23). "Press Release: EQT Private Equity to Sell Ellab, Following Transformation into a Leading Validation & Monitoring Provider for the Biotech and Pharmaceutical Industries"....
• [6] EQT AB. (3/29/23). "Press Release: EQT Life Sciences Closes Dementia Fund at the Hard Cap"....
• [7] va-Q-tec AG. (1/30/23). "Press Release: Management and Supervisory Boards of va-Q-tec AG Recommend Acceptance of EQT Private Equity’s Voluntary Public Takeover Offer". Würzburg....
• [8] EQT AB. (6/22/22). "Press Release: EQT Private Equity to Acquire SPT Labtech, a Fast-growing Laboratory Automation Player Focused on Low-volume Liquid Handling Technology for GBP 650 Million from Battery Ventures". Stockholm....
• [9] EQT AB. (3/1/22). "Press Release: EQT Closes Acquisition of LSP and Introduces EQT Life Sciences"....
• [10] Life Sciences Partners (LSP). (2/11/22). "Press Release: LSP Closes EUR 1 Billion Flagship Fund LSP 7 to Invest in Life Sciences Companies". Amsterdam....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.